Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The recent in-depth analysis of the global basal cell carcinoma treatment market projects a soaring growth trajectory, estimated to burgeon from USD 7.36 billion in 2023 to USD 17.38 billion by the year 2034.
This growth, characterized by a substantial compound annual growth rate (CAGR) of 8.12% during the 2024-2034 period, is largely driven by increasing occurrences of basal cell carcinoma, coupled with innovative advancements in treatment options.
The most common form of non-melanoma skin cancer, basal cell carcinoma, has been the subject of intensive research and development efforts. As a result, new treatment options are emerging, such as AiViva Biopharma's recent promising trial outcomes for AIV001 (Axitinib), an innovative intradermal therapy for patients diagnosed with basal cell carcinoma.
Efforts like these are integral components propelling the market’s expansion.
In 2023, the surgery segment is noted to have garnered the highest revenue, thanks to advanced surgical methodologies, and a surge in demand for minimally invasive procedures. Medications are anticipated to exhibit the fastest CAGR in the ensuing years, with tailored medical solutions and increased regulatory approvals such as Libtayo's nod from the European Commission.
The global basal cell carcinoma treatment market's dynamic growth finds a strong base in end-user segments, especially within hospital settings. Hospitals remain essential for patient care, interdisciplinary collaboration, and spearheading treatment innovations. Specialist clinics are also expected to manifest considerable growth rates due to their targeted and specialized treatment approaches.
The regional analysis indicates North America as the leader in revenue generation for the forecast period, driven by high instances of skin cancers, robust research initiatives, and favorable reimbursement landscapes.
However, the Asia Pacific region is not far behind, forecasted to register the fastest CAGR on the heels of an uptick in skin disease cases, treatment awareness, and international collaborations.
- Medication
- Surgery
- Others
End-User Segmentation Emphasizes Critical Role of Hospitals
- Specialty Clinics
- Hospitals
- Others
Regional Forecast Highlights Prominence of North America and Asia Pacific Markets
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
The comprehensive global basal cell carcinoma treatment market analysis is formulated to aid stakeholders in discerning the nuanced intricacies of market dynamics, high-growth sectors, and the potent strategies adopted by market players that align with current trends and future projections.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value (USD) in 2023 | $7.36 Billion |
| Forecasted Market Value (USD) by 2034 | $17.38 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
Companies Profiled
- NeonMind BioSciences
- Cybin Corp.
- Pfizer Inc.
- Usona Institute
- Numinus
- Jazz Pharmaceuticals
- Havn Life
- Revive Therapeutics
- Seelos Therapeutics
- PharmaTher Holdings Ltd
- NRx Pharmaceuticals Inc.
- Mind Medicine
For more information about this report visit https://www.researchandmarkets.com/r/pgv485
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
